Bristol-Myers says drug slows joint damage in RA

	Tweet

Bristol-Myers Squibb Co. said on Thursday that a late-stage trial showed its experimental Rheumatoid Arthritis drug abatacept slowed the progression of joint damage in patients with the disease.

The results come from additional analysis of phase III trial data that were released last October showing the drug met the main goal of the trial, which was to improve the signs and symptoms of the disease in patients who had failed certain other therapies.

The latest results, which showed a significant inhibition of joint damage, were presented at a conference in Europe. If approved, analysts expect the drug to generate sales of $500 million to more than $1 billion.

Abatacept could be the first in a new class of drugs known as T-cell co-stimulation modulators, which slow the body’s response to inflammation. 

RELATED STORIES:
Ibuprofen puts high risk cardiac patients at risk   Ways to Stop Pain, Limitations from Hand Arthritis   New Pathway Involved in Rheumatoid Arthritis Identified   New Research Registry to Examine Rheumatoid Arthritis in African Americans   Job rates lower for people with arthritic diseases   Is carpal tunnel syndrome cultural?   Statins may increase arthritis risk in elderly women   Remicade doesn’t change cholesterol ratio   Kids with arthritis at increased risk of fracture   More African-Americans burdened by osteoarthritis in multiple large joints   Exercise therapy may aid hip arthritis   Red meat ups risk of rheumatoid arthritis

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]